Azafaros, a private company building a portfolio of disease-modifying therapeutics to become a leader in lysosomal storage disorders (LSDs) focused on addressing neurological symptoms, today announced the completion of patient recruitment in its Phase 3 study evaluating nizubaglustat for the treatment of GM1/GM2 gangliosidoses. Azafaros’ NAVIGATE program consists of two global Phase 3 multi-centre, randomized, placebo-controlled studies designed to evaluate …
Explore
